Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Liabilities (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Total Liabilities data on record, last reported at $59.9 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 19.99% year-over-year to $59.9 million; the TTM value through Sep 2025 reached $59.9 million, down 19.99%, while the annual FY2024 figure was $64.9 million, 31.97% up from the prior year.
  • Total Liabilities reached $59.9 million in Q3 2025 per ABEO's latest filing, down from $82.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $83.7 million in Q1 2024 and bottomed at $23.3 million in Q3 2022.
  • Average Total Liabilities over 5 years is $49.3 million, with a median of $46.6 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: plummeted 49.56% in 2022, then skyrocketed 141.9% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $37.2 million in 2021, then grew by 0.63% to $37.5 million in 2022, then soared by 31.3% to $49.2 million in 2023, then skyrocketed by 31.97% to $64.9 million in 2024, then decreased by 7.76% to $59.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $59.9 million in Q3 2025, $82.7 million in Q2 2025, and $58.0 million in Q1 2025.